Oramed and HTIT to form joint venture for oral drug products

2023-08-03
Pharmaceutical Technology
临床3期疫苗
Oramed and HTIT to form joint venture for oral drug products
Preview
来源: Pharmaceutical Technology
The JV will commence a Phase III clinical trial of oral insulin in the US. Credit: Okrasiuk / Shutterstock.com
Oramed Pharmaceuticals and Hefei Tianhui Biotech (HTIT) have entered an agreement to form a joint venture (JV) to advance oral drug products.
The JV will focus on advancing Oramed’s oral drug delivery technology worldwide and will commercialise the products based on the oral insulin and protein oral delivery pipeline.
Recommended Reports
Oramed and HTIT to form joint venture for oral drug products
Preview
来源: Pharmaceutical Technology
ReportsInnovation in Pharmaceuticals: Pancreatic extract-based compositions GlobalData
Oramed and HTIT to form joint venture for oral drug products
Preview
来源: Pharmaceutical Technology
ReportsInnovation in Pharmaceuticals: Adenovirus-based medicinal compositions GlobalData
View allCompanies IntelligenceOramed Pharmaceuticals IncOramed LtdOravax Medical IncJVView all
The JV will also leverage the manufacturing expertise and technologies of HTIT.
HTIT will invest $60m in the JV in its initial stage while Oramed will make an investment of $10m. Both parties will hold equal stakes.
The JV will hold worldwide marketing rights to oral drug delivery technology and focus on the development and commercialisation of drug products across the globe.
The companies will also commence a Phase III clinical trial of oral insulin in the US.
Oramed CEO Nadav Kidron stated: “HTIT has successfully completed a Phase III oral insulin trial and submitted a new drug application to the National Medical Products Administration with marketing approval currently pending in China.
“HTIT has state-of-the-art facilities, manufacturing capabilities and the know-how needed to produce oral insulin on an international scale.
“This JV is a true opportunity to leverage our strengths, as well as those of our partners to fast-track our pipeline towards commercialisation.”
The company entered agreements with Oravax Medical in March 2021 to form a JV for oral Covid-19 vaccine development.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
-
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。